ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements
Valiant Laboratories approved acquiring up to 1.01% equity in AMPYR Renewable Energy for ₹0.70 Crore. The investment enables captive solar power for its Tarapur plant.
Valiant Laboratories Limited received a credit rating of IND BBB/Stable/IND A2 from India Ratings and Research for bank loan facilities totaling INR 56 Crore.
Valiant Laboratories Limited has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report and 5th AGM notice.
Valiant Laboratories Limited issued a notice for its Annual General Meeting scheduled for September 28, 2026, covering financial adoption, director appointments, and related party transaction approvals.
Valiant Laboratories Limited has filed its Annual Report for the financial year 2025-26, including the notice of its 5th Annual General Meeting.
Valiant Laboratories will invest up to ₹60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences, through preference shares to support its capital base and operations.
Valiant Laboratories announced the re-appointment of two directors and the continuation of another directorship. These changes were approved during the company's board meeting.
Valiant Laboratories Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026, confirming the utilization of funds from its previous rights issue.
Valiant Laboratories approved the re-appointment of directors and a ₹60 Crore investment in its subsidiary, Valiant Advanced Sciences, alongside office relocation plans.
Valiant Laboratories Ltd reported revenue from operations of ₹115.3 Cr (+146.4% YoY) and net profit of ₹21.1 Cr (+1072.2% YoY) for Q1 FY27.
Valiant Laboratories Limited has scheduled a board meeting for August 10, 2026. The board will consider and approve audited financial results for the quarter ended June 30, 2026.
Valiant Laboratories clarified a missing balancing figure in its March 31, 2025 financial results. This correction follows an inquiry from the NSE.
Valiant Laboratories clarified NSE queries regarding missing segment data and audit report formatting for FY26 results. The company re-filed audited statements confirming single-segment operations.
Valiant Laboratories received a ₹0.36 Crore GST demand and penalty order from Navi Mumbai authorities. Other alleged violations totaling approximately ₹12.16 Crore were successfully dropped.
Valiant Laboratories filed its FY26 Annual Secretarial Compliance Report. The company paid a ₹0.02 Crore fine for a minor procedural delay regarding rights issue committee meetings.
Valiant Organics Limited is acquiring 1,86,07,531 shares of Valiant Laboratories from Dhanvallabh Ventures LLP. This inter-se promoter transfer consolidates holdings within the group.
Valiant Laboratories Limited is exploring potential restructuring options across its holding and subsidiary entities. The board aims to achieve strategic synergies and unlock long-term shareholder value.
Valiant Laboratories Ltd confirmed utilization of ₹81.47 Crore raised through its recent rights issue. The monitoring agency reported no deviations from the stated objects.
Valiant Laboratories appointed Rajesh Chheda & Co. and Ketki D Visariya & Co. as auditors for FY 2026-27. The board meeting concluded on May 14, 2026.
Valiant Laboratories Ltd reported revenue from operations of ₹92 Cr (+59.2% YoY) and net profit of ₹1.8 Cr (+157.1% YoY) for Q4 FY26.
Valiant Laboratories approved audited standalone and consolidated financial results for fiscal year 2026. The board took on record an unmodified audit report from statutory auditors.
Valiant Laboratories scheduled a board meeting for May 14, 2026, to approve annual audited financial results. The trading window remains closed until May 16, 2026.
Mr. Bhanudas D. Patil has resigned from his position as Quality Control Manager (Senior Management Personnel) at Valiant Laboratories Limited. The resignation, effective April 22, 2026, was attributed to personal commitments. This departure marks a change in the company's senior leadership team.
Valiant Laboratories Limited has announced the resignation of Mr. Bhanudas D. Patil, Q.C Manager and Senior Management Personnel, effective from the close of business hours on April 22, 2026. The resignation is due to his personal commitments. The company has formally relieved him of his duties as per his request.